Does Medicare Cover Weight Loss Drugs? What Is and Is Not Covered in 2026

Quick answer: No, traditional Medicare does not cover weight loss drugs when they are prescribed for weight loss alone. A federal law from 2003 specifically bars Medicare Part D from paying for any drug used for weight management. The catch is that Medicare does cover the same GLP-1 medications when they are prescribed for an FDA-approved medical condition, so Ozempic and Mounjaro are covered for type 2 diabetes, Wegovy is covered to reduce heart attack and stroke risk in people with obesity and known heart disease, and Zepbound is covered for moderate to severe obstructive sleep apnea. Medicare also covers weight loss surgery for people who meet the medical criteria.

Does Medicare cover weight loss medication at all?

Not for the diagnosis of obesity by itself. The reason is written into law. When Congress created the Part D prescription drug benefit in the Medicare Modernization Act of 2003, it listed several categories of drugs that plans are not allowed to cover, and “agents when used for weight loss” sits on that exclusion list right next to cosmetic drugs and fertility treatment. So even though Medicare covers prescriptions broadly, a plan is legally prohibited from paying for Wegovy, Zepbound, Saxenda or any other medication when the only reason on the chart is to lose weight.

This trips people up because the drug and the dose can be identical to what a covered patient gets. The same semaglutide molecule is sold as Ozempic for diabetes and Wegovy for obesity. Medicare will happily cover Ozempic for a person with type 2 diabetes and refuse Wegovy for a person without it, even though both are weekly semaglutide injections. The label on the box, not the chemistry, decides coverage.

So the honest framing is this. Medicare does not cover weight loss medication as a weight loss benefit. It covers GLP-1 drugs only when they treat a separate, approved medical condition.

Does Medicare cover GLP-1 for weight loss?

Only through a covered medical indication, never for weight loss on its own. GLP-1 receptor agonists are the class of drugs that includes semaglutide and tirzepatide, and they are the ones almost everyone is asking about. Whether Medicare pays comes down to which brand, which condition, and what is documented.

Here is how the major drugs break down under Medicare in 2026.

Drug (active ingredient)	FDA-approved use	Covered by Medicare Part D?
Ozempic (semaglutide)	Type 2 diabetes	Yes, for diabetes. Not for weight loss.
Mounjaro (tirzepatide)	Type 2 diabetes	Yes, for diabetes. Not for weight loss.
Wegovy (semaglutide)	Obesity, plus reducing cardiovascular risk in people with heart disease	Yes, only for the cardiovascular indication. No for weight loss alone.
Zepbound (tirzepatide)	Obesity, plus moderate to severe obstructive sleep apnea	Yes, only for sleep apnea. No for weight loss alone.
Saxenda (liraglutide)	Obesity	No. Weight loss only indication.

The pattern is clear once you see it laid out. A GLP-1 becomes a covered Medicare drug the moment it carries an FDA approval for something other than weight, and the prescriber documents that condition.

Does Medicare cover Ozempic and Mounjaro for weight loss?

No, not for weight loss, but yes for type 2 diabetes, which is what they are approved to treat. Ozempic and Mounjaro are not approved by the FDA for obesity at all. They are diabetes drugs. Their weight loss is a well known side effect, and plenty of people take them off label for that reason, but Medicare will only cover them when the patient has a type 2 diabetes diagnosis on file.

If you do not have diabetes and a clinician prescribes Ozempic purely to help you lose weight, that is an off-label prescription, and Medicare Part D will deny it. You would be paying cash, which for a brand-name GLP-1 typically runs roughly $900 to $1,100 a month at list price before any manufacturer savings program, and most manufacturer copay cards exclude people on Medicare by federal rule.

For people with type 2 diabetes, the math changes completely. Once diabetes is documented, your Part D plan covers Ozempic or Mounjaro, usually after a prior authorization, and you pay the plan copay or coinsurance for that tier instead of the full cash price.

What the diabetes path costs now

There is a real piece of good news buried in recent law. Starting in 2025, the Inflation Reduction Act capped what any Medicare Part D enrollee pays out of pocket for covered drugs at $2,000 for the calendar year. Once your covered drug spending hits that ceiling, you pay nothing more for the rest of the year. For someone with type 2 diabetes on covered Ozempic or Mounjaro, that changes the arithmetic completely, because the old fear of an open-ended coinsurance bill on an expensive injectable is gone as long as the drug is covered for a qualifying diagnosis. You can also spread that $2,000 across the year in level monthly installments through the Medicare Prescription Payment Plan instead of absorbing it all at once early in the year. None of this helps if the drug is denied for weight loss alone, which is exactly why the diagnosis on the chart carries so much weight.

Does Medicare cover Wegovy and Zepbound for weight loss?

Not for weight loss by itself, but both now have a second approved use that opens the door to coverage. This is the most important recent shift, and it is why the answer changed over the past two years.

Wegovy and heart disease

In March 2024 the FDA approved Wegovy to reduce the risk of heart attack, stroke and cardiovascular death in adults who have both obesity (or overweight) and established cardiovascular disease. Soon after, CMS confirmed that Part D plans may cover Wegovy for that cardiovascular indication. So if you have a history of heart disease and qualify on the weight criteria, your plan can cover Wegovy, not as a weight loss drug, but as heart protection. In the SELECT trial that drove the approval, semaglutide cut major cardiovascular events by about 20 percent in this population.

Zepbound and sleep apnea

In late 2024 the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. That gave Zepbound its own non-weight indication, and Part D plans can now cover it for documented sleep apnea. If you snore, wake unrefreshed and have never had a sleep study, that diagnosis is the gate. Without it, Zepbound for weight loss is still not covered.

The average weight loss numbers behind these drugs are real and large. In the STEP trials, Wegovy produced about 15 percent average body weight loss over roughly 68 weeks. In the SURMOUNT trials, Zepbound produced about 20 percent or more at the higher doses. That is why demand is enormous and why coverage rules matter so much to your wallet.

When will Medicare cover weight loss drugs, including in 2025 and 2026?

As of 2026, Medicare still does not cover weight loss drugs for obesity alone, and there is no confirmed date when it will. This is the question with the most confusion online, so here is the straight timeline.

• In November 2024, CMS proposed a rule that would have reinterpreted the law to let Medicare and Medicaid cover anti-obesity medications by treating obesity as a disease rather than weight as a cosmetic concern.
• In April 2025, the incoming administration declined to finalize that proposal. It was not adopted. Coverage for obesity alone did not take effect in 2025.
• Through 2026, the statutory exclusion from 2003 remains in force. Only a new federal rule or an act of Congress can remove it, and neither has happened as of this writing.

So if you read a headline from 2024 saying “Medicare may soon cover weight loss drugs,” that was a proposal that did not become reality. The expansions that did happen are the narrow medical indications above, Wegovy for heart disease and Zepbound for sleep apnea, not blanket obesity coverage. Always confirm the current year’s rule with your specific Part D plan, because Medicare policy can change with each administration and each plan year.

What weight loss drugs and shots does Medicare cover today?

Medicare covers GLP-1 shots only through a qualifying condition, and it does not cover any injection or pill prescribed for weight management alone. To put the covered paths in one place:

1. Diabetes path: Ozempic or Mounjaro, covered with a type 2 diabetes diagnosis.
2. Heart path: Wegovy, covered with obesity plus established cardiovascular disease.
3. Sleep apnea path: Zepbound, covered with obesity plus moderate to severe obstructive sleep apnea.

Every one of these requires the prescriber to document the qualifying condition and usually clear a prior authorization. Saxenda and any compounded GLP-1 fall outside all of these. On the compounding point, be careful. Compounded semaglutide and tirzepatide are not FDA-approved products. They are legally prescribed through licensed clinicians and pharmacies, often through telehealth, but Medicare does not reimburse them and the supply has tightened now that the official shortage of the brand drugs has ended.

One more honest note for anyone tempted to chase a covered diagnosis. The smarter move is not to guess at whether you might “qualify” but to actually measure the things that decide it. Many people carrying extra weight have an undiagnosed driver sitting in their bloodwork, prediabetes creeping toward an A1C that would change everything, a sluggish thyroid, or insulin resistance that makes the scale refuse to move. If the scale will not budge no matter what you eat, it is usually worth seeing your real numbers first. A full 100-plus biomarker panel that includes fasting insulin, A1C and thyroid will tell you whether there is a medical lever to pull, and that documentation is exactly what a clinician needs to justify a covered prescription.

Does Medicare cover weight loss surgery?

Yes. This is the part many people miss while focused on the drugs. Medicare does cover bariatric (weight loss) surgery for people who meet the clinical criteria, and it has for years, because surgery is treated as a covered medical procedure rather than a weight loss “agent.”

To qualify, you generally need to meet all of the following:

• A body mass index of 35 or higher.
• At least one obesity-related condition, such as type 2 diabetes, high blood pressure or sleep apnea.
• Documented previous attempts at medical weight management that did not work.

Covered procedures typically include gastric bypass, sleeve gastrectomy and certain other approved surgeries, performed at a facility that meets Medicare standards. Part A covers the inpatient hospital stay and Part B covers the surgeon and outpatient care, subject to your deductibles and coinsurance. So the irony stands. Medicare will pay tens of thousands of dollars for surgery to treat severe obesity, but not a few hundred dollars a month for the medication that might have prevented the need for it. That gap is exactly what the failed 2024 proposal was trying to close.

How prior authorization and appeals actually work

Coverage on paper does not put the drug in your hand. Almost every GLP-1 passes through a gate called prior authorization, where your Part D plan asks the prescriber to prove the diagnosis before it agrees to pay. Many plans add step therapy on top, which means they want to see that you tried a cheaper option first, for example an older oral diabetes medication before a brand-name GLP-1. Knowing these gates exist lets you clear them on purpose instead of running into them by surprise at the pharmacy counter.

Here is the sequence that works.

1. Ask before you fill. Have the clinic check your plan formulary and confirm whether the drug needs prior authorization or step therapy for your specific diagnosis. That five minute call prevents a full-price shock at the register.
2. Get the paperwork submitted with the right codes. The prior authorization has to carry the diagnosis code that justifies coverage, the diabetes code for Ozempic and Mounjaro, the cardiovascular code for Wegovy, the sleep apnea code for Zepbound. A missing or wrong code is the single most common reason a legitimate prescription gets denied.
3. If it is denied, appeal. Medicare gives Part D members a formal, multi-step appeal. You start by asking the plan for a coverage determination, then a redetermination, then an independent review outside the plan, with further levels above that. A denial is not the end of the road, and plenty of denials are reversed once the documentation is complete.

A realistic example

Picture two people who weigh the same and want the same drug. The first has a chart that says obesity and nothing else, so every GLP-1 is denied for weight loss and the only path is roughly a thousand dollars a month in cash. The second gets a basic lab panel and a sleep study, which turn up an A1C in the prediabetes range drifting toward diabetes and moderate obstructive sleep apnea that nobody had caught. Suddenly there are two documented conditions that can unlock covered Zepbound and, if diabetes is confirmed, covered Mounjaro. Same body, same goal, very different bill, and the only difference was measuring instead of guessing.

Common mistakes and what stalls people on Medicare coverage

The denials and surprise bills almost always come from the same handful of errors. Knowing them ahead of time saves months.

• Asking for the weight loss brand when you qualify for the diabetes one. A person with diabetes who asks for Wegovy may be denied, when Ozempic, the same molecule, would be covered. Match the drug to the diagnosis you actually have.
• Skipping the prior authorization. Nearly all GLP-1 coverage requires it. If your clinician does not submit the paperwork with the diagnosis codes, the pharmacy will charge you full price at the counter and you will assume Medicare “does not cover it.”
• Assuming a manufacturer coupon will help. By federal anti-kickback rules, drug company copay cards cannot be used by people on Medicare. The savings programs you see advertised are for people with commercial insurance.
• Believing the 2024 headlines. The proposal to cover obesity drugs was not finalized. Acting as if coverage already exists leads to denied claims.
• Never getting tested for the condition that would open up coverage. Plenty of people have undiagnosed sleep apnea, prediabetes or cardiovascular risk that, once documented, changes the answer. Guessing leaves money and treatment on the table.

That last point is the one worth sitting with. The difference between a covered prescription and a $1,000 monthly cash bill is often a single test result that no one ever ordered. Talk to a clinician before starting or stopping any medication, and ask specifically what would need to be documented for coverage in your case.

What if Medicare will not cover it for you?

If you do not have a qualifying condition, you have three realistic options, and none of them involves pretending. First, pay cash for the brand drug, which is expensive and rarely sustainable on a fixed income. Second, work with your clinician to see whether a qualifying condition is genuinely present but undiagnosed, which is where real lab work matters. Third, look at the structural levers Medicare does cover, including surgery for those who qualify and the diabetes-path drugs if your blood sugar warrants them.

Two programs are worth checking before you decide the drug is simply out of reach. Extra Help, also called the Part D Low-Income Subsidy, lowers premiums, deductibles and copays for people with limited income and resources, and it can make a covered GLP-1 far cheaper for those who qualify. Some states also run State Pharmaceutical Assistance Programs that help with drug costs on top of Medicare. Neither program pays for a drug that is excluded for weight loss alone, but both can sharply cut the bill for a drug that is covered through a qualifying diagnosis.

Medicare Advantage is a common source of confusion here. An Advantage plan bundles your coverage through a private insurer and sometimes advertises extra supplemental benefits, so people hope it quietly gets around the drug rule. It does not. Advantage plans still follow the same Part D exclusion for weight loss agents, so a GLP-1 prescribed purely to lose weight is no more covered under Advantage than under Original Medicare. Where Advantage can sometimes help is in adjacent benefits, since some plans include fitness memberships, nutrition support or meal benefits, none of which replace the medication but which can support the lifestyle side of the work.

The through-line on this site is simple. Most people fighting their weight are guessing instead of measuring. Before you spend $12,000 a year out of pocket on a drug, it is worth knowing whether your insulin, thyroid, A1C and inflammation markers are quietly working against you, because those numbers both explain the stall and often open the door to covered treatment. People exploring telehealth weight programs may also compare them on cost, and our breakdown of how much Ro weight loss costs shows what the cash route really looks like. If you are on a tight budget and Medicare is a no, it is also worth reading whether Medicaid covers weight loss shots, since the rules there differ by state.

FAQ

Does Medicare cover weight loss injections?

Only when the injection treats a covered condition. Weekly GLP-1 injections like Ozempic, Mounjaro, Wegovy and Zepbound are covered for diabetes, cardiovascular risk or sleep apnea respectively, but not when prescribed solely to lose weight. Saxenda, a daily injection approved only for obesity, is not covered.

Does Medicare cover Ozempic for weight loss?

No. Ozempic is approved for type 2 diabetes, and Medicare covers it only for that diagnosis. If you do not have diabetes and want Ozempic to lose weight, that is an off-label use and Part D will deny it.

Does Medicare cover Wegovy for weight loss?

Not for weight loss alone. Since the 2024 cardiovascular approval, Part D plans can cover Wegovy for adults who have obesity plus established heart disease, to reduce the risk of heart attack and stroke. Without that heart condition, it is not covered.

Does Medicare cover Zepbound for weight loss?

Not for weight loss by itself. After the late 2024 approval for moderate to severe obstructive sleep apnea, Part D plans can cover Zepbound for that documented sleep condition in adults with obesity. A weight loss prescription alone is still excluded.

Does Medicare cover Mounjaro for weight loss?

No. Mounjaro is approved for type 2 diabetes, so Medicare covers it for diabetes, not for weight loss. The obesity version of the same drug is Zepbound, which is covered only for the sleep apnea indication.

When will Medicare cover weight loss drugs?

There is no confirmed date. A 2024 proposal to cover anti-obesity drugs was not finalized in 2025, and as of 2026 the 2003 law that excludes weight loss agents still stands. Only a new federal rule or an act of Congress would change it.

Will Medicare cover weight loss drugs in 2026?

Not for obesity alone, based on current rules. The only 2026 coverage paths are the medical indications, Ozempic and Mounjaro for diabetes, Wegovy for cardiovascular risk and Zepbound for sleep apnea. Confirm specifics with your own Part D plan each year.

Will Medicare cover weight loss surgery?

Yes, for people who meet the criteria, generally a BMI of 35 or higher, at least one obesity-related condition, and documented prior attempts at medical weight management. Approved procedures include gastric bypass and sleeve gastrectomy at qualifying facilities.

What weight loss drugs does Medicare cover?

None for weight loss as the sole reason. It covers GLP-1 drugs only through a qualifying condition, Ozempic and Mounjaro for diabetes, Wegovy for heart disease and Zepbound for sleep apnea. Saxenda and compounded GLP-1s are not covered.

Does Medicare cover compounded semaglutide or tirzepatide?

No. Compounded versions are not FDA-approved products. They are legally prescribed through licensed clinicians and pharmacies, often via telehealth, but Medicare does not reimburse them, and supply has tightened now that the brand-drug shortage has officially ended.

Does Medicare Advantage cover weight loss drugs?

No, not for weight loss alone. Medicare Advantage plans include Part D style drug coverage and follow the same federal exclusion, so a GLP-1 prescribed only to lose weight is not covered. They do cover the same medical indications, diabetes, cardiovascular risk and sleep apnea, and some plans add fitness or nutrition perks that do not replace the drug.

Is there an out-of-pocket cap on covered GLP-1 drugs?

Yes. Since 2025, Medicare Part D caps a member total out-of-pocket drug spending at $2,000 per calendar year. Once you reach it, covered drugs cost you nothing more that year. This applies only to drugs your plan actually covers, so it helps the diabetes, heart and sleep apnea paths, not a weight loss prescription that is excluded.

Can I appeal if Medicare denies my GLP-1?

Yes. If a covered indication applies and the claim was still denied, you can request a coverage determination and then move through the formal Medicare appeal levels, including an independent review outside your plan. Denials tied to missing diagnosis codes or incomplete prior authorization are often overturned once the paperwork is corrected.